BALAXI PHARMACEUTICALS share news, announcements and annual reports
NSE: BALAXIPharmaceuticals & BiotechnologySmall Cap
BALAXI PHARMACEUTICALS LIMITED · Formerly Balaxi Ventures · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Nov 2015
Last close ₹19.75up ₹0.60 (3.13%)
Share price at the NSE close on 2 Nov 2026. Previous close ₹19.15.
2 Nov: open ₹19.60, high ₹19.99, low ₹19.21
52-week range of traded prices to 2 Nov 2026
₹15.20Low, 27 Mar 2026₹43.85High, 4 Nov 2025
- Next results date: the board meets on 12 Nov 2026 to consider: financial results and other business matters. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹109 Cr2,722nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 44.98
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 0.44
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 1.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 2.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.22
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 6,108
BALAXI PHARMACEUTICALS share news and announcements
466 announcements, routine notices left out, newest first. Page 5 of 10.
Jul 2022
15 Jul · Analysts
14 Jul · Analysts
13 Jul · Analysts
11 Jul · Meeting
Jun 2022
18 Jun · Corporate action
18 Jun · Meeting
3 Jun · Related Party Transaction
May 2022
23 May · Communication to shareholders as per Reg 30
23 May · Results
Apr 2022
25 Apr · Management
Feb 2022
9 Feb · Results
9 Feb · Board meeting
Nov 2021
Oct 2021
28 Oct · Results
28 Oct · Board meeting
Aug 2021
25 Aug · Meeting
Jul 2021
30 Jul · Meeting
17 Jul · Results
17 Jul · Board meeting
Jun 2021
May 2021
20 May · Results
20 May · Board meeting
Apr 2021
23 Apr · Business